Fewer than a tenth of individuals that would benefit from weight-loss injections including Wegovy are able to get them, warns the World Health Organization as it issues its first guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for more widespread and fairer access to this class of drugs.
Per projections, over two billion could be obese by 2030 unless action is taken.
"Our latest guidelines recognises that obesity is a lifelong illness that can be managed with holistic and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major hurdles to universal access to the injections that can assist patients in reducing significant body mass, explains the body.
GLP-1 Therapy Scarcity
Despite the current best projected case, the production of these medications might only reach around 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation urges nations and manufacturers to widen access, through approaches including patent sharing.
The intellectual property rights on semaglutide – the core ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
How Obesity Jabs Work
These medications replicate a body's own hormone to slow digestion, reduce hunger and enhance feelings of fullness so individuals consume fewer calories.
Patients usually begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Research points to patients may put most of the weight back on within a year of stopping the medication, when their normal appetite return.
Being carrying excess weight increases your chance for experiencing diseases, such as type 2 diabetes, heart disease, brain attack, and certain malignancies.
Obesity concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
